Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women

Osteoporosis is a metabolic bone disease resulting from increased bone resorption and characterized by low bone mass that leads to increased bone fragility and risk of fracture, particularly of the hip, spine and wrist. Bone resorption is dependent on receptor activator of NF-kappa B ligand (RANKL), which binds to RANK receptor on preosteoclasts to initiate osteoclastogenesis and maintains osteoclast function and survival. To neutralize the effects of RANKL, the body naturally produces the protein osteoprotegerin (OPG), which acts as a decoy receptor for RANKL and contributes to bone homeostasis. We describe the piecewise development of a three-compartment pharmacokinetic model with both linear and Michaelis–Menten eliminations, and an indirect pharmacodynamic response model to describe the pharmacokinetics and pharmacodynamics, respectively, of the fusion protein, Fc-osteoprotegerin (Fc-OPG), in healthy postmenopausal women. Subsequently, model verification was performed and used to address study design questions via simulation. The model was developed using data from eight cohorts (n = 13 subjects/cohort; Fc-OPG:placebo = 10:3) classified by dose level (0.1, 0.3, 1.0, or 3.0 mg/kg) and route of administration (intravenous [IV] or subcutaneous [SC]). Fc-OPG serum concentrations and urinary N-telopeptide/creatinine ratios (NTX) following both IV and SC administration were available. The model provided an adequate fit to the observed data and physiologically plausible parameter estimates. Model robustness was tested via a posterior predictive check with the model performing well in most cases. Subsequent clinical trial simulations demonstrated that a single 3.0-mg/kg SC dose of Fc-OPG would be expected to produce, at 14 days post-dose, a median NTX percentage change from baseline of  −45% (with a 95% prediction interval ranging from −34% to −60%). Lastly, model ruggedness was evaluated using local and global sensitivity analysis methods. In conclusion, the model selection and simulation strategies we applied were rigorous, useful, and easily generalizable.

[1]  M. Ettinger,et al.  Aging bone and osteoporosis: strategies for preventing fractures in the elderly. , 2003, Archives of internal medicine.

[2]  M. Rubin,et al.  The anabolic effects of parathyroid hormone therapy. , 2003, Clinics in geriatric medicine.

[3]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[4]  Hartmut Derendorf,et al.  Pharmacokinetic/pharmacodynamic studies in drug product development. , 2002, Journal of pharmaceutical sciences.

[5]  S. Cremers,et al.  A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis , 2002, European Journal of Clinical Pharmacology.

[6]  K. Blesch,et al.  Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience , 2003, Investigational New Drugs.

[7]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  Roberto Gomeni,et al.  In Silico Prediction of Optimal in Vivo Delivery Properties Using Convolution-Based Model and Clinical Trial Simulation , 2004, Pharmaceutical Research.

[9]  Stephen Duffull,et al.  Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan , 2001, Pharmaceutical Research.

[10]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  D. Ruppert,et al.  Transformation and Weighting in Regression , 1988 .

[13]  J F Boisvieux,et al.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.

[14]  J. Gobburu,et al.  Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. , 2002, International journal of clinical pharmacology and therapeutics.

[15]  L. Hofbauer,et al.  The OPG/RANKL/RANK system in metabolic bone diseases. , 2004, Journal of musculoskeletal & neuronal interactions.

[16]  Timothy Goggin,et al.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.

[17]  M. Draper The Role of Selective Estrogen Receptor Modulators (SERMs) in Postmenopausal Health , 2003, Annals of the New York Academy of Sciences.

[18]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[19]  K. Åkesson New approaches to pharmacological treatment of osteoporosis. , 2003, Bulletin of the World Health Organization.

[20]  W. Colburn,et al.  Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.

[21]  A. van Peer,et al.  A Model with Separate Hepato-Portal Compartment ("First-Pass" Model): Fitting to Plasma Concentration-Time Profiles in Humans , 1997, Pharmaceutical Research.

[22]  Ivan A. Nestorov,et al.  Sensitivity Analysis of Pharmacokinetic and Pharmacodynamic Systems: I. A Structural Approach to Sensitivity Analysis of Physiologically Based Pharmacokinetic Models , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.